ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Update

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the recipient of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 131,700 shares, an increase of 18.4% from the September 15th total of 111,200 shares. Based on an average trading volume of 74,600 shares, the short-interest ratio is presently 1.8 days. Approximately 1.3% of the company’s shares are sold short.

ABVC BioPharma Trading Up 17.4 %

ABVC BioPharma stock opened at $0.59 on Wednesday. ABVC BioPharma has a 1-year low of $0.41 and a 1-year high of $3.35. The firm has a market cap of $6.37 million, a P/E ratio of -0.26 and a beta of 0.81. The firm has a 50-day moving average of $0.66 and a 200-day moving average of $0.85.

ABVC BioPharma (NASDAQ:ABVC) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.09) earnings per share for the quarter. ABVC BioPharma had a negative return on equity of 139.97% and a negative net margin of 8,363.97%. The business had revenue of $0.12 million during the quarter.

Institutional Trading of ABVC BioPharma

An institutional investor recently bought a new position in ABVC BioPharma stock. Chase Investment Counsel Corp bought a new position in ABVC BioPharma, Inc. (NASDAQ:ABVC) in the 1st quarter, according to its most recent disclosure with the SEC. The firm bought 178,377 shares of the company’s stock, valued at approximately $233,000. Chase Investment Counsel Corp owned 1.69% of ABVC BioPharma at the end of the most recent quarter. Institutional investors and hedge funds own 11.38% of the company’s stock.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.